Simplified schematic illustration showing the proposed mechanism of action of FcRn inhibitors. The left side illustrates how IgG molecules enter cells and interact with the neonatal Fc receptors (FcRn), and the right side depicts the impact of FcRn inhibitors on this process. Image by Benff, licensed under [CC BY-SA 4.0], via Wikimedia Commons. Modified from D.D. Patel, J.B. Bussel’s work.
The Fc receptor (FcRn) inhibitor market, led by promising candidates such as efgartigimod, promises to reshape the autoimmune disease treatment landscape. Sales projections for the market top $10 billion, as Driehaus Capital Management estimates. The addressable U.S. patient base spans more than 228,500 individuals across various conditions including myasthenia gravis, warm autoimmune hemolytic anemia (wAIHA) and idiopathic thrombocytopenia purpura (ITP), and more. As the estimated annual treatment cost per patient for targeted…